Literature DB >> 17566121

Manganic encephalopathy due to "ephedrone" abuse.

Yanush Sanotsky1, Roman Lesyk, Lyudmyla Fedoryshyn, Iryna Komnatska, Yuriy Matviyenko, Stanley Fahn.   

Abstract

We describe the clinical and neuroimaging features of 6 drug-abuse patients with self-inflicted manganese poisoning. The patients injected a home-brewed mixture called "ephedrone" (slang term) that contained manganese to produce an amphetamine-like euphoria. The desired chemical product, phenylpropanoneamine (also called methcathinone), was synthesized from a common-cold-remedy compound using permanganate as the catalyst. Manganese was a by-product in the ephedrone mixture. After months of self-injections, a clinical picture emerged, consisting of apathy, bradykinesia, gait disorder with postural instability, and spastic-hypokinetic dysarthria. There was no response to levodopa. The MRI revealed symmetric hyperintense T1-weighted signals in the basal ganglia, typical of manganese accumulation. 2007 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17566121     DOI: 10.1002/mds.21378

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  22 in total

1.  Mechanisms of lead and manganese neurotoxicity.

Authors:  April P Neal; Tomas R Guilarte
Journal:  Toxicol Res (Camb)       Date:  2013-03-01       Impact factor: 3.524

2.  White matter abnormalities in methcathinone abusers with an extrapyramidal syndrome.

Authors:  Ainars Stepens; Charlotte Jane Stagg; Ardis Platkajis; Marie-Hélène Boudrias; Heidi Johansen-Berg; Michael Donaghy
Journal:  Brain       Date:  2010-10-29       Impact factor: 13.501

Review 3.  Manganese and its role in Parkinson's disease: from transport to neuropathology.

Authors:  Michael Aschner; Keith M Erikson; Elena Herrero Hernández; Elena Herrero Hernández; Ronald Tjalkens
Journal:  Neuromolecular Med       Date:  2009       Impact factor: 3.843

4.  Improvement in Ephedrone Parkinsonism After Global Pallidus Pars Interna Deep Brain Stimulation Implantation.

Authors:  Dariusz Koziorowski; Stanislaw Szlufik; Tomasz Mandat; Maria Kloda; Karolina Duszynska-Was; Agnieszka Drzewinska; Andrzej Friedman
Journal:  Mov Disord Clin Pract       Date:  2015-11-14

5.  A distinct variant of mixed dysarthria reflects parkinsonism and dystonia due to ephedrone abuse.

Authors:  Jan Rusz; Marika Megrelishvili; Cecilia Bonnet; Michael Okujava; Hana Brožová; Irine Khatiashvili; Madona Sekhniashvili; Marina Janelidze; Eduardo Tolosa; Evžen Růžička
Journal:  J Neural Transm (Vienna)       Date:  2014-01-21       Impact factor: 3.575

6.  Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease.

Authors:  Marialuisa Quadri; Antonio Federico; Tianna Zhao; Guido J Breedveld; Carla Battisti; Cathérine Delnooz; Lies-Anne Severijnen; Lara Di Toro Mammarella; Andrea Mignarri; Lucia Monti; Antioco Sanna; Peng Lu; Francesca Punzo; Giovanni Cossu; Rob Willemsen; Fabrizio Rasi; Ben A Oostra; Bart P van de Warrenburg; Vincenzo Bonifati
Journal:  Am J Hum Genet       Date:  2012-02-16       Impact factor: 11.025

7.  Increased reflection impulsivity in patients with ephedrone-induced Parkinsonism.

Authors:  Atbin Djamshidian; Yanosh Sanotsky; Yuriy Matviyenko; Sean S O'Sullivan; Stephen Sharman; Marianna Selikhova; Ludmyla Fedoryshyn; Yuriy Filts; Jenny Bearn; Andrew J Lees; Bruno B Averbeck
Journal:  Addiction       Date:  2013-02-11       Impact factor: 6.526

Review 8.  Manganese and Parkinson's disease: a critical review and new findings.

Authors:  Tomás R Guilarte
Journal:  Environ Health Perspect       Date:  2010-04-19       Impact factor: 9.031

9.  Manganese-Induced Parkinsonism due to Ephedrone Abuse.

Authors:  Katrin Sikk; Sulev Haldre; Sten-Magnus Aquilonius; Pille Taba
Journal:  Parkinsons Dis       Date:  2011-02-17

Review 10.  Manganese neurotoxicity: lessons learned from longitudinal studies in nonhuman primates.

Authors:  Neal C Burton; Tomás R Guilarte
Journal:  Environ Health Perspect       Date:  2008-10-03       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.